satavaptan   Click here for help

GtoPdb Ligand ID: 2199

Synonyms: SR 121463A | SR-121463B | SR-121463F | SR121463A
Compound class: Synthetic organic
Comment: This compound was being tested in clinical trials for the prevention of ascites, but in 2008 the pharmaceutical company withdrew its application for marketing authorisation from the European Medicines Agency (EMA). There is some ambiguity in the literature and on other databases as to the exact stereochemistry of Satavaptan. The structure shown here matches the INN document, while the compound is represented on ChEMBL by CHEMBL2107777 and on PubChem by CID 158348.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 12
Topological polar surface area 132.09
Molecular weight 643.29
XLogP 3.53
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCOc1ccc2c(c1)C1(CCC(CC1)OCCN1CCOCC1)C(=O)N2S(=O)(=O)c1ccc(cc1OC)C(=O)NC(C)(C)C
Isomeric SMILES CCOc1ccc2c(c1)[C@@]1(CC[C@H](CC1)OCCN1CCOCC1)C(=O)N2S(=O)(=O)c1ccc(cc1OC)C(=O)NC(C)(C)C
InChI InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+
InChI Key QKXJWFOKVQWEDZ-VCCCEUOBSA-N
References
1. Akerlund M, Bossmar T, Brouard R, Kostrzewska A, Laudanski T, Lemancewicz A, Serradeil-Le Gal C, Steinwall M. (1999)
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
Br J Obstet Gynaecol, 106 (10): 1047-53. [PMID:10519430]
2. Cotte N, Balestre MN, Phalipou S, Hibert M, Manning M, Barberis C, Mouillac B. (1998)
Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.
J Biol Chem, 273 (45): 29462-8. [PMID:9792651]
3. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C et al.. (1996)
Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
J Clin Invest, 98 (12): 2729-38. [PMID:8981918]
4. Serradeil-Le Gal C, Raufaste D, Double-Cazanave E, Guillon G, Garcia C, Pascal M, Maffrand JP. (2000)
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
Kidney Int, 58 (4): 1613-22. [PMID:11012895]
5. Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G. (2006)
Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
Clin J Am Soc Nephrol, 1 (6): 1154-60. [PMID:17699341]
6. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W et al.. (1998)
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Br J Pharmacol, 125 (7): 1463-70. [PMID:9884074]
7. Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A. (2001)
Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
Br J Pharmacol, 133 (5): 746-54. [PMID:11429400]